Press release from PR Newswire
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference
Thursday, May 10, 2012
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference09:30 EDT Thursday, May 10, 2012TARRYTOWN, N.Y., May 10, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012. The presentation is scheduled for 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time). The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page. An archived version of the presentation will be available for 30 days. Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection for Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products. A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion. Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab. Earlier-stage clinical programs are underway with nine additional monoclonal antibodies. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D. Peter DworkinInvestor Relations Corporate Communications 914-847-5126 914-847-7640 firstname.lastname@example.org email@example.comSOURCE Regeneron Pharmaceuticals, Inc.